Gate2Brain, member of CataloniaBio & HealthTech, has announced that it has received funding from EIT Health, a European health innovation network. This investment will allow Gate2Brain to advance the development of its revolutionary technology for drug administration to the brain.
Gate2Brain's technology is based on an artificial blood-brain barrier that allows for precise and efficient drug administration directly to the brain. This improved blood-brain barrier is crucial for the treatment of neurological diseases such as Alzheimer's, Parkinson's and brain tumors, as it overcomes current limitations in drug delivery to the brain.
EIT Health has selected Gate2Brain under its acceleration program, which seeks to identify and finance projects with high potential impact in the field of health. This investment will provide Gate2Brain with the necessary resources to conduct additional preclinical and clinical studies to demonstrate the efficacy and safety of its technology.
Comments